AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
lefamulin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibacterials, pleuromulin derivatives | 5348 | 1061337-51-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
XENLETA is a semi-synthetic antibacterial agent for oral and intravenous administration. Lefamulin inhibits bacterial protein synthesis through interactions (hydrogen bonds, hydrophobic interactions, and Van der Waals forces) with the A- and P-sites of the peptidyl transferase center (PTC) in domain V of the 23s rRNA of the 50S subunit. The binding pocket of the bacterial ribosome closes around the mutilin core for an induced fit that prevents correct positioning of tRNA.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 1.32 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 3.96 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.17 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 6.40 hours | Lombardo F, Berellini G, Obach RS |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
| BA (Bioavailability) | 21 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAP3K7,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,STK33,SYK,TEK,TGFBR1,ZAP70 | 32 | |||
| kinase-selectivity-class | EIF2AK3 | 1 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 19, 2019 | FDA | NABRIVA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01XX12 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Other antibacterials |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| FDA CS | M0006609 | Diterpenes |
| FDA EPC | N0000175434 | Pleuromutilin Antibacterial |
| FDA MoA | N0000182141 | Cytochrome P450 3A4 Inhibitors |
| FDA MoA | N0000190114 | Cytochrome P450 3A Inhibitors |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
Related Drugs by ATC class:
J01XX Other antibacterials 12 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Pneumonia due to Streptococcus | indication | 34020007 | |
| Pneumonia due to Mycoplasma pneumoniae | indication | 46970008 | |
| Bacterial pneumonia | indication | 53084003 | DOID:874 |
| Haemophilus influenzae pneumonia | indication | 70036007 | |
| Legionella pneumonia | indication | 195889001 | |
| Pneumonia due to Staphylococcus aureus | indication | 441658007 | |
| Pneumonia caused by Chlamydia pneumoniae | indication | 724498004 | |
| Bronchopneumonia due to Haemophilus influenzae | indication | 10625231000119106 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.21 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 600MG BASE | XENLETA | HONG KONG | N211672 | Aug. 19, 2019 | RX | TABLET | ORAL | Aug. 19, 2024 | NEW CHEMICAL ENTITY |
| EQ 150MG BASE/15ML (EQ 10MG BASE/ML) | XENLETA | HONG KONG | N211673 | Aug. 19, 2019 | RX | SOLUTION | INTRAVENOUS | Aug. 19, 2024 | NEW CHEMICAL ENTITY |
| EQ 600MG BASE | XENLETA | HONG KONG | N211672 | Aug. 19, 2019 | RX | TABLET | ORAL | Aug. 19, 2029 | GENERATING ANTIBIOTIC INCENTIVES NOW |
| EQ 150MG BASE/15ML (EQ 10MG BASE/ML) | XENLETA | HONG KONG | N211673 | Aug. 19, 2019 | RX | SOLUTION | INTRAVENOUS | Aug. 19, 2029 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Multidrug resistance protein 1 | Transporter | IC50 | 4.47 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 21904A5386 | UNII |
| 1350636-82-6 | SECONDARY_CAS_RN |
| 4038663 | VANDF |
| C4482908 | UMLSCUI |
| CHEBI:755252 | CHEBI |
| 62B | PDB_CHEM_ID |
| CHEMBL3291398 | ChEMBL_ID |
| 58076382 | PUBCHEM_CID |
| DB12825 | DRUGBANK_ID |
| CHEMBL3545309 | ChEMBL_ID |
| D11631 | KEGG_DRUG |
| 9849 | INN_ID |
| C000591018 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10824 | IUPHAR_LIGAND_ID |
| 789396009 | SNOMEDCT_US |
| 789501006 | SNOMEDCT_US |
| 321702 | MMSL |
| 37323 | MMSL |
| d09356 | MMSL |
| 018094 | NDDF |
| 018095 | NDDF |
| 2198943 | RXNORM |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Xenleta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-037 | TABLET, COATED | 600 mg | ORAL | NDA | 27 sections |
| Xenleta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-039 | INJECTION, SOLUTION | 150 mg | INTRAVENOUS | NDA | 27 sections |
| Xenleta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72000-110 | TABLET, COATED | 600 mg | ORAL | NDA | 27 sections |
| Xenleta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72000-120 | INJECTION, SOLUTION | 150 mg | INTRAVENOUS | NDA | 27 sections |